AU2021200638B2 - Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists - Google Patents

Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists Download PDF

Info

Publication number
AU2021200638B2
AU2021200638B2 AU2021200638A AU2021200638A AU2021200638B2 AU 2021200638 B2 AU2021200638 B2 AU 2021200638B2 AU 2021200638 A AU2021200638 A AU 2021200638A AU 2021200638 A AU2021200638 A AU 2021200638A AU 2021200638 B2 AU2021200638 B2 AU 2021200638B2
Authority
AU
Australia
Prior art keywords
oxpapc
lps
caspase
dcs
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021200638A
Other languages
English (en)
Other versions
AU2021200638A1 (en
Inventor
Jonathan C. Kagan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Children's Hospital
Original Assignee
Boston Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016206965A external-priority patent/AU2016206965C1/en
Application filed by Boston Children's Hospital filed Critical Boston Children's Hospital
Priority to AU2021200638A priority Critical patent/AU2021200638B2/en
Publication of AU2021200638A1 publication Critical patent/AU2021200638A1/en
Application granted granted Critical
Publication of AU2021200638B2 publication Critical patent/AU2021200638B2/en
Priority to AU2024219454A priority patent/AU2024219454A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021200638A 2015-01-12 2021-02-01 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists Active AU2021200638B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021200638A AU2021200638B2 (en) 2015-01-12 2021-02-01 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
AU2024219454A AU2024219454A1 (en) 2015-01-12 2024-09-06 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562102245P 2015-01-12 2015-01-12
US62/102,245 2015-01-12
AU2016206965A AU2016206965C1 (en) 2015-01-12 2016-01-12 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
PCT/US2016/012994 WO2016115097A2 (en) 2015-01-12 2016-01-12 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
AU2021200638A AU2021200638B2 (en) 2015-01-12 2021-02-01 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2016206965A Division AU2016206965C1 (en) 2015-01-12 2016-01-12 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024219454A Division AU2024219454A1 (en) 2015-01-12 2024-09-06 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists

Publications (2)

Publication Number Publication Date
AU2021200638A1 AU2021200638A1 (en) 2021-03-04
AU2021200638B2 true AU2021200638B2 (en) 2024-06-06

Family

ID=56406560

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021200638A Active AU2021200638B2 (en) 2015-01-12 2021-02-01 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
AU2024219454A Pending AU2024219454A1 (en) 2015-01-12 2024-09-06 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024219454A Pending AU2024219454A1 (en) 2015-01-12 2024-09-06 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists

Country Status (7)

Country Link
US (7) US20180318414A1 (cg-RX-API-DMAC7.html)
EP (2) EP3244923B1 (cg-RX-API-DMAC7.html)
JP (7) JP2018501322A (cg-RX-API-DMAC7.html)
AU (2) AU2021200638B2 (cg-RX-API-DMAC7.html)
CA (1) CA2973585A1 (cg-RX-API-DMAC7.html)
ES (1) ES3057334T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016115097A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2973585A1 (en) * 2015-01-12 2016-07-21 Children's Medical Center Corporation Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
AU2017356295A1 (en) * 2016-11-14 2019-05-23 Beth Israel Deaconess Medical Center Compositions and methods of treating cancer
EP3946456A4 (en) * 2019-03-29 2023-05-03 The Brigham and Women's Hospital, Inc. TARGETED SYNERGISTIC CANCER IMMUNOTHERAPY
MX2022004186A (es) * 2019-10-07 2022-07-19 Northwest Biotherapeutics Inc Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1.
EP4061423A4 (en) * 2019-11-18 2023-12-06 Children's Medical Center Corporation HYPERACTIVE DENDRITIC CELLS FOR PERMANENT ANTITUMOR EFFECT ON ADOPTIONAL CELL TRANSFER BASIS
US20230076515A1 (en) * 2019-11-18 2023-03-09 Children's Medical Center Corporation Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy
CN114894910B (zh) * 2022-03-18 2023-10-20 重庆医科大学附属第一医院 1-棕榈酰-2-花生四烯酰-sn-甘油-3-磷酸胆碱检测试剂的新用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026384A1 (en) * 1998-11-03 2000-05-11 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
WO2004006910A1 (de) * 2002-07-15 2004-01-22 Norbert Leitinger Lipidoxidationsprodukte zur hemmung von entzündungen
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US8961982B2 (en) * 2005-12-16 2015-02-24 The Regents Of The University Of California Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
CA2702340C (en) * 2006-10-12 2014-12-16 The University Of Queensland Compositions and methods for modulating immune responses
WO2011013682A1 (ja) 2009-07-27 2011-02-03 株式会社神戸製鋼所 配線構造およびその製造方法、並びに配線構造を備えた表示装置
US20130108661A1 (en) 2010-02-05 2013-05-02 Mount Sinai School Of Medicine Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
CA2798074A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
CA2840170A1 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
EP2791101B1 (en) * 2011-12-12 2019-09-18 Vascular Biogenics Ltd. Treatment of non-alcoholic steatohepatitis
WO2014164699A1 (en) 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
EP3083945B1 (en) 2013-12-18 2020-03-18 Julius-Maximilians-Universität Würzburg Galactose oxidase treatment of dendritic cells to improve their immunogenicity
CA2973585A1 (en) * 2015-01-12 2016-07-21 Children's Medical Center Corporation Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
PT3291821T (pt) 2015-05-07 2026-03-18 Baylor College Medicine Imunoterapêutica com células dendríticas
CN117244049A (zh) 2016-02-16 2023-12-19 哈佛学院院长等 病原体疫苗及其生产和使用方法
US11266746B2 (en) 2016-06-27 2022-03-08 The United Slates of America, as represented by the Secretary, Department of Health and Human Services Therapeutic antitumor combination of a TLR4 ligand with other treatments
WO2018067302A2 (en) 2016-09-19 2018-04-12 North Western University Therapeutic effects of cellular delivery of small molecules and macromolecules with liposomal spherical nucleic acids
JP7355394B2 (ja) 2018-05-03 2023-10-03 エル.イー.エー.エフ. ホールディングス グループ エルエルシー カロテノイド組成物およびその使用
MX2022004186A (es) 2019-10-07 2022-07-19 Northwest Biotherapeutics Inc Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1.
US20230076515A1 (en) 2019-11-18 2023-03-09 Children's Medical Center Corporation Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy
EP4061423A4 (en) 2019-11-18 2023-12-06 Children's Medical Center Corporation HYPERACTIVE DENDRITIC CELLS FOR PERMANENT ANTITUMOR EFFECT ON ADOPTIONAL CELL TRANSFER BASIS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026384A1 (en) * 1998-11-03 2000-05-11 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KNAPP, S. et al. "Oxidized Phospholipids Inhibit Phagocytosis and Impair Outcome in Gram-Negative Sepsis In Vivo", The Journal of Immunology, 2007, Vol. 178, pages 993-1001 *

Also Published As

Publication number Publication date
JP2023055880A (ja) 2023-04-18
JP2018501322A (ja) 2018-01-18
EP3244923B1 (en) 2025-10-01
JP7719816B2 (ja) 2025-08-06
AU2021200638A1 (en) 2021-03-04
JP7719815B2 (ja) 2025-08-06
EP3244923A2 (en) 2017-11-22
JP2021059571A (ja) 2021-04-15
US12070499B2 (en) 2024-08-27
CA2973585A1 (en) 2016-07-21
JP2025090801A (ja) 2025-06-17
JP2025094038A (ja) 2025-06-24
JP7410845B2 (ja) 2024-01-10
US20200405847A1 (en) 2020-12-31
WO2016115097A2 (en) 2016-07-21
WO2016115097A3 (en) 2016-09-09
EP4681782A3 (en) 2026-04-15
US20230053338A1 (en) 2023-02-23
JP7410846B2 (ja) 2024-01-10
US20180318414A1 (en) 2018-11-08
US12053522B2 (en) 2024-08-06
US11351250B2 (en) 2022-06-07
JP2021059570A (ja) 2021-04-15
EP3244923C0 (en) 2025-10-01
AU2016206965A1 (en) 2017-08-31
US20250025552A1 (en) 2025-01-23
US20240415957A1 (en) 2024-12-19
EP3244923A4 (en) 2018-09-05
JP2023055883A (ja) 2023-04-18
AU2016206965B2 (en) 2021-03-04
ES3057334T3 (en) 2026-02-27
US20200405848A1 (en) 2020-12-31
AU2024219454A1 (en) 2024-10-03
US11400153B2 (en) 2022-08-02
EP4681782A2 (en) 2026-01-21
US20230042429A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
US12070499B2 (en) Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
Chuang et al. Adjuvant effect of toll-like receptor 9 activation on cancer immunotherapy using checkpoint blockade
AU2021204595B2 (en) Macrophages eat cancer cells using their own calreticulin as a guide
US10155014B2 (en) Cyclic di-AMP induction of type I interferon
Choi et al. Mycobacterium tuberculosis RpfE promotes simultaneous Th1‐and Th17‐type T‐cell immunity via TLR4‐dependent maturation of dendritic cells
CN112888707A (zh) T细胞受体构建体及其用途
CA2978496A1 (en) Method
C Junquera et al. Recent advances in the development of anti-Infective prophylactic and/or therapeutic agents based on toll-like receptor (TLRs)
US20240100133A1 (en) Enzymatically inactive granzyme a and uses therefore
WO2023097237A2 (en) Cytosolic bacterial pathogens attenuated for spread from tumors and methods of use thereof
HK40053747A (en) T cell receptor constructs and uses thereof
WO2017098281A1 (en) Therapeutic agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)